Mar 3 |
This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year
|
Mar 2 |
Earnings Update: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Just Reported And Analysts Are Boosting Their Estimates
|
Mar 1 |
Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy?
|
Mar 1 |
Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?
|
Mar 1 |
Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice
|
Mar 1 |
Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade
|
Mar 1 |
Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why
|
Mar 1 |
Protagonist Therapeutics Full Year 2023 Earnings: Beats Expectations
|
Feb 29 |
We're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn
|
Feb 28 |
Protagonist GAAP EPS of $0.44
|